---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275862"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:26:04.376319+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development

## Summary
- 10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).
- Proceeds to advance telitacicept clinical development including Phase 3 trial for primary Sjögren's Disease, plus manufacturing/pre-commercialization.
- Offering expected to close November 12, 2025; underwriters have 30-day option for up to 1,500,000 additional shares.
- As of Sept 30, 2025, outstanding shares were 9,026,922; offering represents ~111% dilution if fully exercised.
- Company believes current cash plus proceeds will fund operations into Q2 2027.

## SEC filing metadata
- accession: 0001193125-25-275862
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/0001193125-25-275862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525275862/vor-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275862
- JSON: https://secwatch.observer/filing/0001193125-25-275862.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.